Drug Profile

Isaralgagene civaparvovec - Sangamo Therapeutics

Alternative Names: ST 920

Latest Information Update: 30 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sangamo Therapeutics
Class Gene therapies
Mechanism of Action Alpha-galactosidase replacements; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Fabry's disease
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I/II Fabry's disease

Most Recent Events

25 Jun 2025 Efficacy and adverse events data from a phase I/II STAAR trial in Fabry's disease released by Sangamo Therapeutics
06 May 2025 Sangamo Therapeutics announces intention to submit BLA to US FDA for Fabry's disease, in the first quarter of 2026
06 May 2025 Sangamo Therapeutics anticipates a potential approval and commercial launch as early as the second half of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com